Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc. (CRVS)
:CRVS
CRVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.54 - $10.00
Previous CloseN/A
Volume202.27K
Average Volume (3M)479.21K
Market Cap
$412.81M
Enterprise Value$237.77M
Total Cash (Recent Filing)$74.41M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Oct 30, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding74,514,040
10 Day Avg. Volume538,194
30 Day Avg. Volume479,211
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue2.70K
Enterprise Value/Gross Profit-8.81K
Enterprise Value/Ebitda-6.70
Forecast
1Y Price Target
$12.33Price Target Upside124.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical ProgressCorvus Pharmaceuticals is advancing its atopic dermatitis clinical program and is ready to move soquelitinib into a Phase 2 study following strong results.
Regulatory ApprovalsThe company's partner in China, Angel Pharmaceuticals, has received regulatory clearance to initiate a Phase 1/2 study in China, expanding the geographical scope of clinical testing.
Bears Say
Financial PerformanceFor the quarter, the company reported no revenues and a net loss of $0.13 per diluted share, compared to consensus estimated net loss of $0.12 per share.
Market ReactionThe significant drop in CRVS shares is seen as an overreaction, potentially due to market disappointment with soquel's efficacy compared to Dupixent.
Corvus Pharmaceuticals News
CRVS FAQ
What was Corvus Pharmaceuticals Inc.’s price range in the past 12 months?
Corvus Pharmaceuticals Inc. lowest stock price was $2.54 and its highest was $10.00 in the past 12 months.
What is Corvus Pharmaceuticals Inc.’s market cap?
Corvus Pharmaceuticals Inc.’s market cap is $412.81M.
When is Corvus Pharmaceuticals Inc.’s upcoming earnings report date?
Corvus Pharmaceuticals Inc.’s upcoming earnings report date is Oct 30, 2025 which is in 62 days.
How were Corvus Pharmaceuticals Inc.’s earnings last quarter?
Corvus Pharmaceuticals Inc. released its earnings results on Aug 07, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.033.
Is Corvus Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc.’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc. pay dividends?
Corvus Pharmaceuticals Inc. does not currently pay dividends.
What is Corvus Pharmaceuticals Inc.’s EPS estimate?
Corvus Pharmaceuticals Inc.’s EPS estimate is -0.13.
How many shares outstanding does Corvus Pharmaceuticals Inc. have?
Corvus Pharmaceuticals Inc. has 74,514,040 shares outstanding.
What happened to Corvus Pharmaceuticals Inc.’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 4.358%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in CRVS
Corvus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (124.18% Upside)
$12.33 (124.18% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.13%
12-Months-Change
Fundamentals
Return on Equity
-68.67%
Trailing 12-Months
Asset Growth
38.57%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
CRVS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical progress, particularly with soquelitinib, and a strong cash position, offset by increased net loss and R&D expenses. The positive clinical data and financial stability indicate a promising outlook despite financial challenges.View all CRVS earnings summariesCRVS Stock 12 Month Forecast
Average Price Target
$12.33
▲(124.18% Upside)
Technical Analysis
Ownership Overview
22.98% Insiders
4.20% Mutual Funds
27.32% Other Institutional Investors
37.84% Public Companies and
Individual Investors